Regeneron Pharmaceuticals (REGN) Reports Promising Phase 1/2 Trial Data Amid Stock Price Dip
· gurufocus.com
On October 01, 2026, Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced initial results from its Phase 1/2 clinical trial of ubamatamab targeting low-grade
On October 01, 2026, Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced initial results from its Phase 1/2 clinical trial of ubamatamab targeting low-grade ...